G Mariani

1.5k total citations
33 papers, 917 citations indexed

About

G Mariani is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G Mariani has authored 33 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G Mariani's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Melanoma and MAPK Pathways (5 papers) and Cancer therapeutics and mechanisms (5 papers). G Mariani is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Melanoma and MAPK Pathways (5 papers) and Cancer therapeutics and mechanisms (5 papers). G Mariani collaborates with scholars based in Italy, United States and United Kingdom. G Mariani's co-authors include Thomas W. Grunt, Jens Rüter, Divis Khaira, Tiziana Usari, Patricia LoRusso, Denis Soulières, Susan M. Domchek, Prudence Dorazio, Magi Khalil and Robert H. Vonderheide and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

G Mariani

31 papers receiving 890 citations

Peers

G Mariani

ONCOL

PRM

IMMUN

Robert P. Whitehead United States

Christopher Ruel United States

M. Thomas France

Brian Belmontes United States

M Volm Germany

Prashanth Prithviraj Australia

Brian S. Henick United States

Philipp Manegold United States

Shane K. Green Canada

Robert P. Whitehead United States

G Mariani

527 ×0.9

ONCOL

285 ×0.8

189 ×0.7

PRM

176 ×0.8

IMMUN

162 ×1.4

Citations per year, relative to G Mariani G Mariani (= 1×) peers Robert P. Whitehead

Countries citing papers authored by G Mariani

Since Specialization

Citations

This map shows the geographic impact of G Mariani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Mariani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Mariani more than expected).

Fields of papers citing papers by G Mariani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Mariani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Mariani. The network helps show where G Mariani may publish in the future.

Co-authorship network of co-authors of G Mariani

This figure shows the co-authorship network connecting the top 25 collaborators of G Mariani. A scholar is included among the top collaborators of G Mariani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Mariani. G Mariani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elks, Cathy E., Paul Martin, David Carlile, et al.. (2017). Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology. 73(6). 717–726. 12 indexed citations

Soria, J.C., Carlos Dias Maciel, Jürgen R. Fischer, et al.. (2017). SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 28(12). 3028–3036. 24 indexed citations

Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2017). Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer. JAMA. 317(18). 1844–1844. 249 indexed citations

Howes, Colin, et al.. (2016). Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. Clinical Therapeutics. 38(11). 2447–2458. 24 indexed citations

Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Annals of Oncology. 27. vi583–vi583. 10 indexed citations

So, Karen, Paul Martin, Yifan Huang, et al.. (2016). Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. European Journal of Clinical Pharmacology. 73(2). 175–184. 23 indexed citations

Zhou, Diansong, Karen So, Nidal Al‐Huniti, et al.. (2016). Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Clinical Therapeutics. 38(12). 2555–2566. 3 indexed citations

Grunt, Thomas W. & G Mariani. (2013). Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling. Current Cancer Drug Targets. 13(2). 188–204. 71 indexed citations

Vonderheide, Robert H., Patricia LoRusso, Magi Khalil, et al.. (2010). Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. Clinical Cancer Research. 16(13). 3485–3494. 234 indexed citations

10.

Numico, Gianmauro, Federico Castiglione, Cristina Granetto, et al.. (2002). Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 35(1). 59–64. 24 indexed citations

11.

Ardizzoni, Andrea, Marco Danova, Claudio Viscoli, et al.. (1996). Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. British Journal of Cancer. 74(7). 1141–1147. 7 indexed citations

12.

Ardizzoni, Andrea, M. Venturini, M.R. Sertoli, et al.. (1994). Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. British Journal of Cancer. 69(2). 385–391. 58 indexed citations

13.

Ardizzoni, Andrea, Editta Baldini, Anna Verna, et al.. (1994). Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer. 73(5). 1353–1360. 27 indexed citations

14.

Ardizzoni, Andrea, M.C. Pennucci, B. Castagneto, et al.. (1994). Recombinant Interferon Alpha-2b in the Treatment of Diffuse Malignant Pleural Mesothelioma. American Journal of Clinical Oncology. 17(1). 80–82. 29 indexed citations

15.

Russo, Patrizia, Monica Valenti, Silvio Parodi, et al.. (1993). Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. European Journal of Cancer. 29(8). 1157–1161. 13 indexed citations

16.

Valenti, Monica, et al.. (1993). Potentiation of TNF-mediated cell killing by mitoxantrone. Biochemical Pharmacology. 46(7). 1199–1206. 7 indexed citations

17.

Venturini, M., Lucia Del Mastro, Andrea Ardizzoni, et al.. (1993). High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte‐Macrophage Colony‐Stimulating Factor^a. Annals of the New York Academy of Sciences. 698(1). 389–397. 1 indexed citations

18.

Rosso, R., et al.. (1992). An outpatient phase I study of a subcutaneous interleukin-2 and intramuscular alpha-2a-interferon combination in advanced malignancies. Annals of Oncology. 3(7). 559–563. 8 indexed citations

19.

Russo, Patrizia, et al.. (1991). Human Granulocyte‐Macrophage Colony‐stimulating Factor Is a Growth Factor Active on Human Ovarian Cancer Cells. Japanese Journal of Cancer Research. 82(11). 1196–1198. 16 indexed citations

20.

Mandelli, F, et al.. (1969). [2 cases of congenital hypoconvertinemia].. PubMed. 9(4). 485–94. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact